重新审视临床淋巴结阴性甲状腺乳头状癌的预防性中央区颈清扫
本文讨论临床淋巴结阴性(cN0)甲状腺乳头状癌是否应行预防性中央区颈清扫。尽管中央区微小转移常见且术前超声常漏诊,但未行该清扫时临床淋巴结复发率低于10%,生存获益未获证实,且可能增加暂时性甲状旁腺功能减退的并发症。指南对此仍持开放讨论态度,作者建议新的研究方向。
要点
- cN0甲状腺乳头状癌中央区微小转移常被超声漏诊,仅预防性清扫可发现。
- 未行预防性中央区颈清扫时,临床淋巴结复发率低于10%。
- 预防性清扫未显示生存优势,且可能增加暂时性甲状旁腺功能减退。
核心结论
- 预防性中央区颈清扫在cN0甲状腺乳头状癌中的获益与风险仍存争议,生存优势未获证实。
研究设计与样本
- 本文为Personal View,总结当前争议与证据并建议研究方向。
主要发现
- 中央区微小转移常见且术前超声常无法检出(cN0),仅系统性预防性清扫可识别。
- 即使未行预防性中央区颈清扫,临床检测到的淋巴结复发率低于10%。
- 临床数据未显示生存优势,部分研究提示区域复发率 incremental 降低但暂时性甲状旁腺功能减退并发症增加。
关键数值与推荐
- 指南过去十年对预防性中央区颈清扫保持开放讨论,由临床医生决策。
临床怎么用
- 临床医生需在cN0甲状腺乳头状癌中权衡预防性中央区颈清扫的潜在复发降低与并发症风险。
局限性
- 外科随机试验实施困难,解决该争议仍具挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Papillary thyroid cancer is associated with a high rate of lymph node metastases, mainly in the form of small metastases in the central compartment. Even when present, these metastases are most often undetected by preoperative ultrasound (clinically node-negative or cN0) and only identified by systematically performing a prophylactic central neck dissection. However, even in the absence of prophylactic central neck dissection to remove these metastases, clinically detected recurrence in lymph nodes occurs in fewer than 10% of patients, which explains the controversy surrounding the procedure. Clinical data have not shown an advantage in survival, although some studies point to an incremental reduction in regional recurrence rates with a concomitant increase in morbidity in temporary hypoparathyroidism. Thus, over the past decade, guidelines have kept the option of prophylactic central neck dissection open for discussion, leaving clinicians to make these decisions. Resolving this issue remains a challenge due to the difficulties inherent in implementing randomised trials in a surgical setting. This Personal View aims to summarise the current controversy and evidence surrounding prophylactic central neck dissection and to suggest new directions for research.
引用
- Hartl DM, Schlumberger M. Rethinking prophylactic central neck dissection in clinically node-negative papillary thyroid cancer. Lancet Diabetes Endocrinol. 2026. PMID: 42114521. doi:10.1016/S2213-8587(26)00071-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。